Quote Request
Whole-Exome Sequencing for Pancreatic Cancer
Advances in whole-exome sequencing (WES) have shed light on the mutational profile and clonal evolution of pancreatic cancer, providing insights into its development. Alfa Cytology, a global leader in life sciences, offers pancreatic cancer exome sequencing services to support researchers in drug development and exploring new treatment options.
Overview of Exome Sequencing for Pancreatic Cancer
WES focuses on sequencing the protein-coding regions of the genome, representing about 1% of the total human genome, yet covering regions where the majority of known disease-related mutations occur. WES has emerged as a critical tool in pancreatic cancer research for identifying somatic mutations, including key driver mutations such as those in KRAS, TP53, and SMAD4, which are commonly associated with pancreatic ductal adenocarcinoma (PDAC). By selectively targeting exons, WES enables researchers and clinicians to uncover actionable mutations and genetic alterations that play a pivotal role in tumorigenesis, disease progression, and therapeutic response.
Fig. 1 Revised genetic progression model of pancreatic cancer of the most commonly altered genes. (Hayashi, A., et al., 2021)
WES offers a cost-effective approach to understanding the molecular landscape of pancreatic cancer, providing detailed insights that can aid in the development of targeted therapies and precision medicine. As a non-invasive diagnostic tool, WES also supports the identification of germline mutations that may predispose individuals to hereditary pancreatic cancer syndromes. Furthermore, combining WES with other omics technologies, such as transcriptomics and proteomics, enhances the ability to develop comprehensive molecular profiles that inform treatment decisions and improve clinical outcomes.
Our Services
Exome sequencing targets coding regions likely to have mutations impacting tumor progression. Alfa Cytology offers integrated research and development services from early discovery to preclinical research. Our whole-exome sequencing service for pancreatic cancer includes:
Exome Capture and Library Preparation: Targeted sequencing of protein-coding regions using high-quality DNA from tumor samples.
Sequencing and Data Analysis: Next-generation sequencing (NGS) technology to generate high-coverage data, followed by bioinformatic analysis for mutation detection, variant annotation, and interpretation.
Mutation Profiling: Identification of driver mutations, copy number variations, and genetic alterations relevant to pancreatic cancer.
Reporting and Interpretation: Comprehensive reports that include identified mutations, pathway analysis, and potential therapeutic targets.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
WES can provide mutational information that can indicate potential targets for personalized diagnostic and therapeutic interventions, as well as the optimal timing of interventions. If you are interested in our services, please contact us. We are glad to work with you!
Reference
- Hayashi, A., Hong, J. & Iacobuzio-Donahue, C.A. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 18, 469–481 (2021).
